ConductScience.org, home

Paper8551569

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Trkola A and 9 others. J Virol, 1996. Cited by 991 papers, by iCite.

Cite this record

ConductScience Library. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Papers, record 8551569. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8551569

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
PubMed
Journal
J Virol
PubMed
Year
1996
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
991
iCite
Relative citation ratio, by iCite
22.6
iCite
Revised in PubMed
2025-09-03
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Trkola AA
2Purtscher MM
3Muster TT
4Ballaun CC
5Buchacher AA
6Sullivan NN
7Srinivasan KK
8Sodroski JJ
9Moore JPJ P
10Katinger HH

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Epitope MappingMajor topic
HIV AntibodiesMajor topic
HIV Envelope Protein gp120Major topic
HIV-1Major topic
Amino Acid Sequence
Antibody-Dependent Cell Cytotoxicity
Cell Line
Complement C3
Giant Cells
Glycosylation
Humans
Molecular Sequence Data
Mutation
Neutralization Tests
Polysaccharides

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
N01 AI35168NIAID NIH HHSUnited StatesN01AI035168PubMed and NIHNIH RePORTER
R01 AI25541NIAID NIH HHSUnited StatesR01AI025541PubMed and NIHNIH RePORTER
R01 AI36082NIAID NIH HHSUnited StatesR01AI036082PubMed and NIHNIH RePORTER

Download CSV of grants

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11700828Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis.J Virol1990https://conductscience.org/library/papers/1700828PubMed
27769703Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.J Virol1995https://conductscience.org/library/papers/7769703PubMed
31702163Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.J Virol1991https://conductscience.org/library/papers/1702163PubMed
42014246Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.Proc Natl Acad Sci U S A1991https://conductscience.org/library/papers/2014246PubMed
51863402Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group.AIDS1991https://conductscience.org/library/papers/1863402PubMed
61717717Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.J Virol1991https://conductscience.org/library/papers/1717717PubMed
71717992Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.Proc Natl Acad Sci U S A1991https://conductscience.org/library/papers/1717992PubMed
81718036Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.Science1991https://conductscience.org/library/papers/1718036PubMed
91370558Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.J Virol1992https://conductscience.org/library/papers/1370558PubMed
101722676Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1.AIDS1991https://conductscience.org/library/papers/1722676PubMed
111724568A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.Res Virol1991https://conductscience.org/library/papers/1724568PubMed
121599752Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.AIDS Res Hum Retroviruses1992https://conductscience.org/library/papers/1599752PubMed
131380099Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.J Virol1992https://conductscience.org/library/papers/1380099PubMed
141381201Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.AIDS Res Hum Retroviruses1992https://conductscience.org/library/papers/1381201PubMed
151381908Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.Arch Virol1992https://conductscience.org/library/papers/1381908PubMed
161388899Complement-mediated, antibody-dependent neutralizing titers of sera from asymptomatic and symptomatic HIV-infected individuals.AIDS1992https://conductscience.org/library/papers/1388899PubMed
177677959Complement activation by human monoclonal antibodies to human immunodeficiency virus.J Virol1993https://conductscience.org/library/papers/7677959PubMed
188417177Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.J Acquir Immune Defic Syndr (1988)1993https://conductscience.org/library/papers/8417177PubMed
197678308Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.J Virol1993https://conductscience.org/library/papers/7678308PubMed
207685405Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.J Virol1993https://conductscience.org/library/papers/7685405PubMed

See all 60 referencesDownload CSV of references

Cited by648

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 991 citations.

PMIDTitleJournalYearIn PapersSource
42774884Direct detection and quantification of HIV particles and their envelope trimers bound by combinations of broadly neutralizing antibodies.iScience2026https://conductscience.org/library/papers/42774884PubMed
42322610Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic.Cell Rep2026https://conductscience.org/library/papers/42322610PubMed
42207948Endocytic motif on HIV-1 Env regulates cleavage status and antibody neutralization of cell-free and cell-to-cell infection.J Virol2026https://conductscience.org/library/papers/42207948PubMed
42051541Comparing CD8+ T cell ENV epitopes of two HLA class I alleles associated with different outcomes of HIV-1 infection with broadly neutralizing antibodies epitope targets discovered to date.Front Immunol2026https://conductscience.org/library/papers/42051541PubMed
42019079Structural Insights Into Man9 Recognition by the HIV Antibody 2G12 Revealed by Paramagnetic NMR.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42019079PubMed
41939861Immunomodulation by glycosylation: bridging glycobiology to adaptive immunity and therapeutic innovation.Front Immunol2026https://conductscience.org/library/papers/41939861PubMed
41917410The Biological Role of Enveloped Virus Glycosylation and Its Interactions with Antiviral Lectins.Adv Exp Med Biol2026https://conductscience.org/library/papers/41917410PubMed
41789059Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.Front Immunol2026https://conductscience.org/library/papers/41789059PubMed
41648506Functional Convergence of Genetically Diverse B-Cell Receptors in Simian-HIV Infected Rhesus Macaques.bioRxiv2026https://conductscience.org/library/papers/41648506PubMed
41497656Comprehensive Mapping of the Virus and Host Factors that Guide the Paths of HIV-1 Escape from a Therapeutic.bioRxiv2025https://conductscience.org/library/papers/41497656PubMed
40726783In Vitro Selection of Cyclized, Glycosylated Peptide Antigens That Tightly Bind HIV High Mannose Patch Antibodies.ACS Cent Sci2025https://conductscience.org/library/papers/40726783PubMed
40511646Germline-Targeting Strategies to Induce bNAbs against HIV-1.Curr HIV Res2026https://conductscience.org/library/papers/40511646PubMed
39988778The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials.Curr HIV Res2026https://conductscience.org/library/papers/39988778PubMed
39932316Activation of CXCR3+ Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development.J Virol2025https://conductscience.org/library/papers/39932316PubMed
39836706Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity.PLoS Pathog2025https://conductscience.org/library/papers/39836706PubMed
39495223Cell-autonomous targeting of arabinogalactan by host immune factors inhibits mycobacterial growth.Elife2024https://conductscience.org/library/papers/39495223PubMed
39163866An explainable language model for antibody specificity prediction using curated influenza hemagglutinin antibodies.Immunity2024https://conductscience.org/library/papers/39163866PubMed
39122901Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing.Commun Biol2024https://conductscience.org/library/papers/39122901PubMed
38979012Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.iScience2024https://conductscience.org/library/papers/38979012PubMed
38675791Nanocapsules Comprised of Purified Protein: Construction and Applications in Vaccine Research.Vaccines (Basel)2024https://conductscience.org/library/papers/38675791PubMed

See all 648 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
C3718PubTator's text mininghttps://conductscience.org/library/genes/718NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
ITIH43700PubTator's text mininghttps://conductscience.org/library/genes/3700NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8551569

GET https://conductscience.org/api/papers/v1/8551569/references?page=2